PCV178 Health Care Stakeholders' Evaluation of A User-Friendly Tool Which Estimates Long-Term Health Gains Following the Reduction of Ldl Levels  by Laires, P.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A503
were to home, 25% to rehabilitative care then home, 2% to rehabilitative care then a 
nursing home, 7% to long-term care and 6% of stays ended with a patient death. Of 
a total cost over 1 year of € 610 million (mean cost per patient of € 20,326), 70% con-
cern the post-acute phase. By increasing the proportion of patients thrombolyzed, 
costs are reduced primarily by a decrease in rehabilitative care, with savings per 
additional treated patient of € 1,462. By adding improved timing, savings are more 
than doubled (€ 3,183 per additional patient). ConClusions: By improving throm-
bolytic management in stroke units, patient journeys through care pathways can 
be modified, with increased discharges home, a change in post-acute resource 
consumption and net savings.
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LaunChing noVeL CLass iii imPLantabLe CardiaC deViCes for 
CardioLogy in euroPe first, is this Common CommerCiaL PraCtiCe 
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objeCtives: Regulatory hurdles for novel medical devices are lower in Europe 
than in the US. The costs and evidence requirements to achieve CE marking for 
class III devices are lower than to achieve FDA-approval via a PMA submission. As 
such, many companies have chosen to enter European markets with innovative 
cardiac devices before entering the US market. This study sought to understand 
the frequency with which that has occurred in the last 10 years, and the correlation 
between market access timing and cardiac outcomes. Methods: A review of CE 
mark and FDA approvals for class III implantable cardiac devices was conducted for 
the period of 2003-2013. Devices were identified and cross referenced to determine 
which products achieved both CE mark and FDA approval. Those with both, were 
then compared by the date of approval to determine market access variance in the 
US versus Germany. Publically available coverage and reimbursement policies were 
reviewed in each market in combination with relevant disease prevalence rates over 
the study period. Results: Implantable cardiac devices were routinely available in 
Germany before the US during the study period. Early use across Europe, in many 
cases, created additional evidence that was leveraged during the FDA approval and 
follow-on reimbursement assessment processes in the US. While HTAs for devices 
was relatively rare in Germany, similar rates of reimbursement and access were 
achieved in both markets. Rates of cardiovascular associated mortality have dropped 
dramatically, across both markets though rates initiated their decline earlier in 
Germany. ConClusions: Germans benefited from earlier access to many innova-
tive implantable cardiac devices during the period of 2003 to 2013, as compared to 
their American counterparts. The link between early access, clinical outcomes, and 
cost needs to be further analyzed in future studies.
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objeCtives: To identify cardiologists willing to participate in Health outcome or 
Clinical Studies Phase III/IV in internal medicine and to include patients for out-
come assessment. Real life and Peri/Post-Approval Studies are becoming more and 
more important to meet regulatory and market access needs. The objective of the 
present contribution is to assess the benefits of a managed panel of cardiologists 
for site and patient recruitment. Methods: In 2012, a representative survey among 
members of a managed physician panel of cardiologists in US, UK, GER, FR, IT and 
SP was conducted. 208 cardiologists reported on former experiences with clinical 
studies phase III/IV and other post-approval studies, their willingness to participate 
in future studies and their potential adherence to requirements of Good Clinical 
Practice rules. Results: 87,6% of the cardiologists reported to have formerly par-
ticipated in clinical studies phase III/IV, and 54,3% in post-approval studies. Over 
58% of these cardiologists were willing to participate in future studies (58,2% in 
clinical studies phase III/IV and 63,1% in other post-approval studies). More than 
92,7% of this group was ready to be named as principal investigator to an ethical 
committee, to report serious events to the sponsor (97,6%), or to participate in a 
web-based training session (90,3%). Within one month cardiologists see in average 
175 patients suffering from chronic heart disease in their practices (Minimum: 20; 
Maximum more than 500). 93,5% of the cardiologists are willing to ask their patients 
for informed consent for participation in studies, thereby providing a promising 
source for recruiting patients. ConClusions: Cardiologists from a managed panel 
are a time- and cost-effective option for recruiting sites and patients for obser-
vational post-approval outcome and safety studies in the big 5 EU countries and 
the US. Patient incidence estimates are a reliable source for enrollment planning.
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of LdL LeVeLs
Laires P.
Merck Sharp & Dohme, Oeiras, Portugal
objeCtives: Demonstration of long-term value of preventive care in terms of health 
gains and avoided costs associated with disease progression may be of great value 
for those who need to prioritize health policies. This analysis aimed to evaluate 
physicians’ and primary care payers’ opinions about a user-friendly tool which esti-
mates long-term health gains following LDL-C reduction. Methods: A user-friendly 
tool was developed based on a previously published Markov model employed to 
evaluate health outcomes, including cardiovascular (CV) events and due costs. The 
model incorporated Framingham risk equations, Portuguese population characteris-
tics, national mortality rates and local costs. Software runs in iOS and the user may 
simulate for 3, 5 and 10 years the expected CV events drop following a given LDL-C 
PCV173
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objeCtives: Hospital admissions for congestive heart failure (CHF) are a major 
driver of costs for health systems, and CHF is especially prevalent in patients 
aged 65 and older. This study assessed whether provision of oral nutritional sup-
plements (ONS) in the hospital can reduce these costs, by estimating the effect 
of ONS use on 30-day readmission rates, length of stay (LOS), and hospitaliza-
tion episode costs. Methods: Using the 2000-2010 Premier Research database, 
a large US hospital episode database, we extracted a sample of episodes among 
patients aged 65 and older with a primary diagnosis of CHF. We excluded episodes 
involving tube feeding and those ending in death (due to censoring). Using pro-
pensity score matching, we created a 1: 1 matched sample of ONS and non-ONS 
episodes. We applied ordinary least squares (OLS) and instrumental variables 
(IV) regression analyses to investigate the outcomes of ONS use. The key out-
comes studied were 30-day readmission rates, LOS, and episode costs (measured 
in 2010 US$). Results: Propensity score matching produced a matched sample 
of 38,418 CHF episodes. Naïve OLS analysis, which did not account for selection 
bias, suggested that ONS increased costs, LOS, and probability of 30-day readmis-
sion. However, using IV regression analysis to control for selection bias revealed 
that ONS use reduced the probability of readmission within 30 days by 10.1%, 
from 0.387 to 0.360 (p< 0.01). LOS was reduced through ONS use by 1.28 days 
(14.2%), from 9.03 to 7.75 (p< 0.01). Episode costs were significantly lower with 
ONS use, reducing medical expenditures by $1,266 (7.8%), from $16,166 to $14,900 
(p< 0.01). ConClusions: In elderly patients hospitalized with CHF, ONS improves 
30-day readmission, LOS, and episode cost outcomes. ONS use could provide a 
low-cost strategy for improving hospitalization outcomes for elderly patients with 
CHF and reducing burden on health systems from CHF.
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objeCtives: The choice of stent used in percutaneous coronary intervention (PCI) 
is often at the discretion of the interventional cardiologist (IC) without informed 
shared decision making. We aim to assess the impact of ICs’ awareness of the risk of 
delayed arterial healing associated with drug-eluting stents (DES) on patient knowl-
edge transfer. Methods: 132 ICs from 11 countries (3 Asian: Malaysia, Hong Kong, 
Singapore and 8 European: Germany, Italy, UK, The Netherlands, Belgium, Denmark, 
Russia and Serbia) were invited to complete an online survey using a 4-point scale 
regarding their (i) familiarity with delayed arterial healing associated with DES; (ii) 
how concerned they are about delayed arterial healing; (iii) frequency they discuss 
this risk with their patients and (iv) frequency this risk influence the type of stent they 
use. Responses from Asian cardiologists were compared with Europeans. Results: 
43.2% ICs were Asians and 56.8% were Europeans. Majority of IC were extremely/
very familiar with the risk of delayed arterial healing after DES implantation (63.2% 
Asian vs. 56.0% European, p= NS). IC who were extremely/very concerned about the 
risk of delayed healing were more likely to discuss with their patients (Odds Ratio 
(OR) 2.62, 95% confidence interval (CI) 1.17-5.85, p< 0.01) and influence their stent 
choice (OR 5.56,95%CI 2.56-12.05, p< 0.01). Although twice as many Asian compared 
to European ICs were extremely/very concerned about delayed arterial healing with 
DES (59.6% vs. 32.4%, respectively, p< 0.01), there were no significant differences in the 
frequency this risk was discussed with patients (often/always: 24.6% Asian vs. 26.7% 
European, P= NS) or influence the type of stent used (often/always: 47.4% vs. 35.7%, 
P= NS). ConClusions: Many patients are not well informed of the risk associated 
with DES despite high level of physician awareness and concern of this risk. This 
knowledge transfer gap exists in both Asia and Europe.
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objeCtives: This study aims to evaluate the current management and associ-
ated costs of acute ischemic stroke (AIS) for patients admitted in stroke units 
in France and over a 1 year follow-up period as well as to assess the impact 
of improved thrombolytic management in terms of increasing the proportion 
of patients receiving thrombolysis and/or treated within 3hrs from symptom 
onset on functional recovery and care pathways. Methods: A decision model 
was developed, comprising two components: the first corresponding to the acute 
hospital management phase of patients with AIS up until hospital discharge and 
the second corresponding to the post-acute phase. Patient journeys and costs were 
determined for both phases. Improved thrombolytic management was modeled 
by increasing the proportion of patients receiving thrombolysis from the current 
estimated level of 16.7 to 25% as well as subsequently increasing the proportion of 
patients treated within 3 hours of the onset of symptoms post-stroke from 50 to 
100%. The impact on care pathways was derived from clinical data. Results: In 
2011, 29,999 stays took place in a stroke unit for AIS in France. 60% of discharges 
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normalized ratio (INR) monitoring in patients on vitamin K antagonists (VKA) on 
maintenance anticoagulation. Methods: This interim analysis is based on data of 
2863 patients enrolled in the PREFER in VTE registry in 7 Western European countries 
(France, Germany, Italy, Spain, UK, Austria and Switzerland). 1689 had DVT (only) 
and 1174 had PE (±DVT). Results: At 6-month follow-up, 51.5% of the patients were 
treated with VKA. INR measurements at 6-month follow-up (UK: 3 month) were 
performed in the hospital setting for 13.1% of these patients (most frequently in 
Spain 42.9%, UK 32.7%,, Italy 18.0%), in the anticoagulation center in 23.6% (in Spain 
40.0%, Italy 37.0%, UK 16.4%), in the physician’s office in 16.8% (Germany 90.7%, UK 
41.8%), by the patient self-measured in 4.9% (Spain 8.6%), or at biology labs or other 
institutions in 36.9% (France 92.4%). The patient’s mean travel distance to the INR 
site was 5.8 ±9.16 km overall, the range was 0-90 km (mean varied across countries 
from 2.4 to 7.7 km). Mean travel time was 14.3 ±18.4 min (across countries 5.7 to 
18.2 min). Patients most frequently used their private car/motorbike (50.8 %) or 
walked (16.4%). The mean number of INR measurements over the 6-month period 
was 16.8, the number of INR measurements per month was 2.8 ±1.2 overall (across 
countries 1.8 to 3.2). ConClusions: In the various countries, different institu-
tions are responsible for routine INR measurements. While biology labs are almost 
exclusively used in France, there is no equivalent for such institutions in other 
countries. INR self-measurement plays a minor role. Patients usually have the INR 
sites in their vicinity, and the average number of measurements shows little vari-
ation between countries.
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objeCtives: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and 
accounts for one-third of hospitalizations for cardiac disturbances. The majority 
of descriptive data on management of AF patients are from western countries, 
with limited information available from the Middle East region. The objective of 
this study was to characterize treatment patterns and health resource utilization 
among AF patients in the Kingdom of Saudi Arabia (KSA) and United Arab Emirates 
(UAE). Methods: A retrospective chart review was undertaken at three hospitals 
in UAE and three in KSA, to identify AF patients diagnosed between January 2005 
and June 2010. Patient charts were sampled consecutively backwards by diagnosis 
date, from June 2010 until the target sample was reached. AF was identified based 
on ICD-9 code (427.31), from a sample of patients defined by any history of antico-
agulant use. Data on demographic and disease-related characteristics, treatment 
patterns, health resource utilization, and international normalized ratio (INR) con-
trol were abstracted from diagnosis until June 2012. Results: Among eligible AF 
patients (UAE, n= 157, KSA, n= 152), the majority were diagnosed with chronic AF 
(80.9% in UAE, 63.7% in KSA) as opposed to paroxysmal AF. Treatments prescribed to 
AF patients differed between countries: warfarin monotherapy was widely used in 
UAE (59.9%), while a variety of warfarin- and aspirin-based combination therapies 
were used in KSA, with no single dominant regimen. Warfarin + bisoprolol (12.5%) 
and aspirin + bisoprolol (10.5%) combination therapies were the most common 
regimens in KSA. Patterns of health care utilization also varied, with hospitalization 
and emergency room visits more common in KSA, and outpatient visits more com-
mon in UAE. ConClusions: Treatments and health resources used by AF patients 
varied between KSA and UAE. While some differences may result from differences 
in patient and disease characteristics, they likely also reflect variation in manage-
ment strategies across the regions.
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aPheresis in Patients at high risk for CardioVasCuLar eVents in 
germany
Villa G.1, Schmid T.2, Lothgren M.1, Michailov G.2
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen GmbH, München, Germany
objeCtives: Individuals at high risk for cardiovascular events who fail to achieve 
treatment goal (LDL-C< 100 mg/dL) despite being on maximal lipid lowering treat-
ment qualify for apheresis, a procedure that costs approximately 40,000€ per patient 
per year in Germany. The current model aims to assess the ability of evolocumab 
(AMG 145), an investigational medication that is being evaluated in clinical trials, 
to reduce the proportion of patients requiring apheresis in Germany. Methods: 
Data on secondary prevention patients eligible for apheresis, excluding homozygous 
familial hypercholesterolemia patients, were extracted from the German IMS Disease 
Analyzer 2011-2013 database (n= 8,262) and included in the analysis. The calculated 
mean LDL-C reductions observed in the DESCARTES and LAPLACE-2 evolocumab tri-
als, ranging from 59.3% (95% CI [54.9%, 63.8%]) to 72.3% (95% CI [69.1%, 75.4%]), were 
applied to baseline LDL-C levels of the identified patient-profiles, following a proba-
bilistic approach. The goal for such patients was LDL-C< 100 mg/dL, as defined in the 
German lipid association (DGFF) guideline. Results: The mean ± standard deviation 
LDL-C levels of the sample decreased from 150.2 ± 32.9 mg/dL at baseline to 61.1 ± 
13.8 mg/dL (DESCARTES) and to 41.7 ± 9.5 mg/dL (LAPLACE-2) after evolocumab treat-
ment. From an initial proportion of 100% of patients eligible for apheresis at baseline, 
evolocumab treatment led to a proportion of 1% (DESCARTES) and 0% (LAPLACE-2) 
of patients requiring apheresis. Thus, in the analyzed population, apheresis-related 
costs could be largely reduced. ConClusions: The use of evolocumab in the treat-
ment algorithm of high-risk patients not at LDL-C goal could allow reducing the 
invasive, time-consuming, burdensome and costly weekly apheresis treatments. As a 
result, significant savings of apheresis-related costs could be achieved by the German 
Health Care System.
reduction. A predefined questionnaire was delivered to physicians’ and primary 
care payers’ (namely members of the regional health authorities) to survey their 
opinions about the value of this tool. Results: Overall opinion from 30 physicians 
and 11 primary care deciders (geographically distributed) was positive, averaging 
3.9 in a likert scale from 1 (strongly disagree) to 5 (strongly agree). Physicians aver-
aged 4 while primary care payers’ was 3.7. 71% of respondents ranked 4 to 5 in 
this overall assessment of the tool. Regarding more specific topics using the same 
likert scale, global, physicians’ and primary care deciders’ responses averaged as 
following, respectively: Utility of the tool: 3.6, 3.6 and 3.6; Relevance of the tool: 3.9, 
3.9 and 3.9; Value of the tool to understand LDL-C treatment targets: 4.0, 4.2 and 
3.6. ConClusions: This approach is useful to understand user’s opinions about a 
tool which aims primarily to raise awareness on the importance of the LDL-C reduc-
tion. Available evidence demonstrates that health care stakeholders in Portugal still 
need to understand the public health potential of LDL reduction. This tool might be 
of great value to address this need.
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objeCtives: Clinical guidelines recommend ACEIs (angiotensin converting enzyme 
inhibitors), ARBs (angiotensin receptor II blockers) for patients intolerant to ACEI, beta 
blockers (BBs), aldosterone antagonists (AAs) and diuretics as the pharmacological 
treatment for heart failure (HF). This study assesses the treatments prescribed within 
30 days post diagnosis among HF patients in a real world setting based on an admin-
istrative claims database in the US. Methods: This was a retrospective cohort study 
conducted using MarketScan database. Adult patients having ≥ 2 HF-related medical 
claims or 1 hospitalisation with primary HF diagnosis between April 2009 and March 
2012, and with a minimum of 12 months pre- and post-index continuous medical 
and pharmacy eligibility were included. Index date was defined as the first HF-related 
medical claim between April 2009 and March 2012. Patients with HF diagnosis in the 
12 months pre-index period were excluded. Demographics, clinical characteristics 
and index treatment (defined as a 30 days window period after HF diagnosis) were 
analysed. Results: Among 121,904 patients included in the analysis, 48.3% were > 75 
years of age and 35.0% were 18-64 years of age. Diabetes (27.0%), CV related condi-
tions (26%) and COPD (16.3%) were the most prevalent comorbidities. Overall, 37.6% 
patients were not prescribed any treatment related to HF within the first 30 days 
after HF diagnosis (no HF severity available). Among those prescribed treatment, the 
following treatment breakdown was observed: ACEIs, 29.3% of patients; ARBs, 8.5%; 
BBs, 46.6%; AAs, 7.4%; and diuretics, 45.7%. Prescription of fixed dose combination of 
ACEIs with diuretics or ARBs with diuretics was very limited. ConClusions: Findings 
suggest that a substantial proportion of patients do not receive HF specific medica-
tions following the month of diagnosis. Further research is necessary to explore the 
reasons for lower than expected HF medication claims in these patients considering 
their high risk for morbidity and mortality.
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1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro,, 2Faculty of 
Medicine, University of Belgrade, Belgrade, Serbia and Montenegro
objeCtives: Benzodiazepines (BZD) are often administered to patients with arterial 
hypertension in addition to antihypertensive agents. The aim of this study was to 
analyze patterns of BSD usage among hypertensive outpatients in Serbia according 
to sex and age. Methods: Data on BZD issued on prescription for the International 
classification of diseases (ICD) code I10 (essential arterial hypertension) were col-
lected from all state-owned pharmacies in Novi Sad (population 350,000) from 
September 2011 to February 2012. Consumption was calculated using the ATC/
DDD methodology. Results: BZD accounted for 2% of all drugs issued in treat-
ment of hypertension. The total amount of BZD issued was 2.27 DDD/1000inh/day. 
Bromazepam (51.38 %) and diazepam (37.56 %) were the most commonly used BSD 
and accounted for almost 90% of all BSD utilized. Lorazepam accounted for 8.36% 
of total consumption. Other agents (alprazolam, nitrazepam, midazolam, klonaz-
epam) accounted for less than 3% altogether. The BZD consumption increased with 
patient’s age – 91% being prescribed to the patients over the age of 50. Consumption 
was highest in age group 70-80 years. BZD were more often prescribed to female 
(68.63%) than to male outpatients (31.37%). ConClusions: This study confirmed 
consumption of BZD among outpatients with hypertension. It is most common 
in hypertensive female and elderly population. However, since the benefits of 
BZD administration in hypertension control remain unclear, the adequacy of this 
practice is questionable. This work was supported by the Ministry of Science and 
Technological Development, Republic of Serbia, project No. 41012.
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objeCtives: In patients with acute deep venous thrombosis (DVT) or pulmonary 
embolism (PE) there is a lack of comparative data on the logistics of international 
